Moreover, RAPA-201 therapy, which has been thought to block the expression of PD-1, CTLA-4, TIM-3, and LAG3, thereby improving the immune suppressive tumor microenvironment, is currently being trialed in a phase I/II study for patients with solid cancer (including breast cancer) (NCT05144698). Here, CTLA4 is linked to neoplasm.